Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints oncology development head

Dr Fouad Namouni promoted from head of medical

BMS Dr Fouad NamouniBristol-Myers Squibb has promoted Dr Fouad Namouni to oncology development head.

In his new role, Dr Namouni will oversee the development strategy for the pharmaceutical firm's oncology pipeline from early stage development through to commercialisation.

He will remain a member of the research and development leadership team, reporting to chief scientific officer and executive vice president Francis Cuss.

Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions in research and development.

On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab). He most recently served as head of medical.

Cuss said: “Fouad has demonstrated highly successful strategic and visionary leadership in oncology and immuno-oncology drug development and medical affairs throughout his career at Bristol-Myers Squibb.

“As a trained pediatric oncologist, Fouad brings to this role exceptional clinical experience and an unwavering commitment to patients.

“I am confident that our oncology development programmes will continue to thrive under his leadership.”

27th July 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics